May 28, 2024
Ebola Vaccine Market

The Global Ebola Vaccine Market Is Driven By Increased Government Funding For Ebola Vaccine Development

Ebola vaccine helps in providing effective protection against deadly Ebola virus that causes Ebola virus disease known as Ebola hemorrhagic fever. It induces the immune system to produce antibodies that recognize and fight off the Ebola virus, similar to other vaccines. The vaccine is administered in multiple doses to achieve maximum level of immunization against Ebola virus. Manufacturers are extensively focusing on research and development activities to come up with more effective Ebola vaccines with long lasting immunity. The global Ebola Vaccine Market is estimated to be valued at US$ 6.72 Billion in 2024.

Market key Trends:

One of the prominent trends contributing to the growth of Ebola vaccine market is increasing partnerships and collaborations among key players and research institutes. For instance, In September 2021, the Coalition for Epidemic Preparedness Innovations entered into an agreement with Precisa Medicamentos to accelerate the development of next generation Ebola vaccines that offer long lasting immunity with single dose administration. This partnership aims to develop vaccines with novel platforms such as mRNA that can induce protective antibody levels with greater effectiveness. Furthermore, growing number of clinical trials for testing different candidate vaccines is promoting the advancement of effective Ebola vaccines.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the Ebola Vaccine market is low as research and development requires significant capital investment and time for new players to enter the market.
Bargaining power of buyers: The bargaining power of buyers is moderate as there are limited vaccine options currently and buyers cannot threat to move to other therapeutic alternatives.
Bargaining power of suppliers: The bargaining power of suppliers is high as manufacturing high-quality vaccines requires specialized expertise and scale. Suppliers can influence pricing to an extent.
Threat of new substitutes: Currently, there is no effective vaccine substitute for Ebola. However, new drug research may lead to therapeutic substitutes.
Competitive rivalry: The competitive rivalry is intense as major players compete based on research & development, pricing strategies and marketing.

Key Takeaways

The global Ebola Vaccine Market Growth is expected to witness high growth. The outbreak of the virus in Africa has increased focus on vaccine development.

Regional analysis:

North America is expected to dominate the Ebola Vaccine market owing to heavy investments in research and presence of key market players. Africa is also expected to grow at a high rate led by increase in prevalence and government focus on control and prevention of the virus.

Key players:

Key players operating in the Ebola Vaccine market are 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode. These players are focused on strengthening their clinical pipelines and development of new vaccines to target the virus.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it